Eupraxia Pharmaceuticals is trading at $7.30 (5.6% up) in pre-market as investors respond to a wave of positive analyst coverage and recent financing momentum.
- Cantor Fitzgerald, Raymond James, and other firms have reiterated bullish ratings and double-digit price targets, highlighting a favorable risk/reward profile ahead of upcoming EP-104GI data.
- The company’s cash position was recently strengthened by successful equity offerings, providing the capital necessary to support its clinical pipeline and ongoing operations.